213PResponse to neoadjuvant chemotherapy in HER2 non-overexpressing breast cancer subtypes
ConclusionsNo correlation between pCR and the level of HER 2 expression was found neither in luminal nor in TNBC patients. In TNBC patients, differences in terms of pCR were noticed between the 3 HER expression groups. The predictive role of HER2 expression should be further explored in early localized TNBC in a larger population.Editorial acknowledgementIsabel Gregoire, medical writer, Department of Biostatistics Georges Francois Leclerc Cancer Center, Dijon, France.Legal entity responsible for the studyThe authors.FundingHas not received any funding.DisclosureAll authors have declared no conflicts of interest.
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | Chemotherapy | Fish | France Health | HER2 | Hormones | Legislation | Neoadjuvant Chemotherapy Therapy | Neoadjuvant Therapy | Statistics